Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada Clears Antibiotic Combo Of India’s Orchid

This article was originally published in PharmAsia News

Executive Summary

India's Orchid Chemicals and Pharmaceuticals got Canadian clearance to sell its combination piperacillin-tazobactam antibiotic. The Therapeutic Products Directorate allowed the combination of antibiotic injections for treating bacterial infections. Piperacilin is based on penicillin and tazobactam enhances its effectiveness. (Click here for more

You may also be interested in...



Wyeth To See First Copies Of Tazocin In EU From Orchid Chemicals

MUMBAI - U.S. drug maker Wyeth will see its first competition in Europe for key antibiotic drug Zosyn, or Tazocin, from Indian drug maker Orchid Chemicals. After almost a wait of more than a year, Orchid received approvals or Marketing Authorization for piperacillin/tazobactum injectibles in the EU countries

A Closer Look: India Patent Disputes Heat Up For Big Pharma

MUMBAI - Multinational pharmaceutical companies eyeing the growing Indian market may find themselves confronting a challenging patent environment during the next few years as public interest groups look to further intensify patent oppositions

India’s Patent Office Rules Against Boehringer Ingelheim Viramune Patent

MUMBAI - India's Patent Office in New Delhi on June 19 discarded a patent application for a pediatric version of German drug maker Boehringer Ingelheim's antiretroviral drug Viramune (nevirapine)

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel